UCAR T-cell Therapy (CD19/BCMA)

Allogeneic CAR-T cell therapy targeting CD19 and BCMA

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for UCAR T-cell Therapy (CD19/BCMA), covering 2026-04-15 to 2026-04-15. Get the full timeline:

Most recent: Clinical Trial Update: UCAR T-cell Therapy Targeting CD19/BCMA in Relapsed/Refractory Autoimmune Hemolytic Anemia [EARLY_Phase 1]